someone explain gastric emptying to me like I have not read a paper in years
Trying to get a straight answer on this: someone explain gastric emptying to me like I have not read a paper in years.
Why mechanism talk keeps misleading people, including me.
A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.
The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.
The mental model, in four steps, that makes the rest of this site legible.
One: gut hormones amplify the insulin response to food. Two: agonists at those receptors act peripherally on insulin secretion and gastric emptying, and centrally on appetite. Three: structural modification gives them a long half-life, so exposure is smooth and weekly. Four: tolerance develops to some effects and not to others.
From those four, most of what the experience boards report falls out: why the side effects cluster early, why they settle at a stable dose, why appetite reduction persists, and why the scale and the appetite move on different clocks.
Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Started reading limitations sections first. It has changed how much weight I give to almost everything posted here.
Started reading limitations sections first.
tomas_lundgren is right that mechanism gives direction and not magnitude. Worth pinning.
Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.
Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.
tolerance to the gastric effect develops, appetite effect largely persists
Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.